Boston Scientific Reports Third Quarter 2024 Financial Results
Intellectia.AI
Boston Scientific Reports Third Quarter 2024 Financial Results
Boston Scientific Corporation (NYSE: BSX) has announced its financial results for the third quarter of 2024, showcasing significant growth and exceeding market expectations.
Key Financial Metrics:
| Metric | Q3 2024 | Q3 2023 | YoY Change | QoQ Change | Consensus Estimate |
|---|---|---|---|---|---|
| Total Revenue | $4.209B | $3.527B | +19.4% | N/A | $4.041B |
| GAAP Net Income | $469M | $505M | -7.1% | N/A | N/A |
| GAAP Earnings Per Share (EPS) | $0.32 | $0.34 | -5.9% | N/A | N/A |
| Adjusted EPS | $0.63 | $0.50 | +26% | N/A | $0.59 |
Boston Scientific's financial performance in Q3 2024 was robust, with total revenue increasing by 19.4% year-over-year, surpassing consensus estimates. Despite a slight decline in GAAP net income, the adjusted EPS showed a significant improvement, reflecting the company's operational efficiency and strategic initiatives.
Revenue Performance by Segment:
| Segment | Q3 2024 Revenue | YoY Growth | Previous Guidance |
|---|---|---|---|
| MedSurg | $1.479B | +10.3% | 13-15% |
| Cardiovascular | $2.731B | +25.0% | 13-15% |
The Cardiovascular segment led the growth with a 25% increase in revenue, driven by strong demand for heart devices. The MedSurg segment also performed well, although slightly below previous guidance.
Operational Highlights:
- FDA approval for the FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software.
- CE mark for the ACURATE Prime™ Aortic Valve System.
- Completion of the acquisition of Silk Road Medical, Inc.
Management Commentary:
Mike Mahoney, Chairman and CEO, highlighted the company's strong performance as a result of its talented global team and strategic focus on product innovation and market leadership.
Dividends and Share Repurchase Program:
No new dividends or share repurchase programs were announced in this quarter.
Forward Guidance:
Boston Scientific has raised its full-year 2024 guidance, expecting net sales growth of approximately 16.5% on a reported basis and 15% on an organic basis. The company projects GAAP EPS to range between $1.28 and $1.30, with adjusted EPS expected to be between $2.45 and $2.47.
Stock Price Movement:
Following the earnings release, Boston Scientific's stock rose by 1.1% in premarket trading, reflecting investor confidence in the company's strong financial performance and positive outlook.
For more in-depth analysis and insights, stay tuned with our platform to stay ahead of the market.
Share
Want more financial insights delivered directly to your inbox?
Subscribe now and receive handpicked financial news, insights, and trending topics.
